Supplementary Fig S3 from Development of an Automated Liquid Biopsy Assay for Methylated Markers in Advanced Breast Cancer

Fackler, Mary Jo; Tulac, Suzana; Venkatesan, Neesha; Aslam, Adam J.; de Guzman, Timothy N.; Mercado-Rodriguez, Claudia; Cope, Leslie M.; Downs, Bradley M.; Vali, Abdul Hussain; Ding, Wanjun; Lehman, Jennifer; Denbow, Rita; Reynolds, Jeffrey; Buckley, Morgan E.; Visvanathan, Kala; Umbricht, Christopher B.; Wolff, Antonio C.; Stearns, Vered; Bates, Michael; Lai, Edwin W.; Sukumar, Saraswati

doi:10.1158/2767-9764.22544652.v1

sorry, we can't preview this file

crc-22-0133-s03.docx (50.76 kB)

Supplementary Fig S3 from Development of an Automated Liquid Biopsy Assay for Methylated Markers in Advanced Breast Cancer

journal contribution

posted on 2023-04-04, 01:24 authored by Mary Jo Fackler, Suzana Tulac, Neesha Venkatesan, Adam J. Aslam, Timothy N. de Guzman, Claudia Mercado-Rodriguez, Leslie M. Cope, Bradley M. Downs, Abdul Hussain Vali, Wanjun Ding, Jennifer Lehman, Rita Denbow, Jeffrey Reynolds, Morgan E. Buckley, Kala Visvanathan, Christopher B. Umbricht, Antonio C. Wolff, Vered Stearns, Michael Bates, Edwin W. Lai, Saraswati Sukumar

Figure shows the perfomance of LBx-BCM in the training set samples. A histogram shows cumulative methylation for each sample, and a box plot shows significnt difference of methylation in serum of metastatic breast cancer patients compared to normal individuals (Mann Whitney p= 0.002)

Funding

U.S. Department of Defense (DOD)

Cepheid (Cepheid Inc)

Avon Foundation for Women (AFW)

Susan G. Komen (SGK)

History

ARTICLE ABSTRACT

We technically validated an automated, cartridge-based, liquid biopsy prototype assay, to quantitatively measure breast cancer methylation in serum or plasma of patients with MBC, that demonstrated high sensitivity and specificity.